The Combat Combination

COMPOSITION – Cilnidipine 10 mg + Telmisartan IP 40 mg 




  • Class of medications: Calcium blockers
  • Centrally acting as dihydropyridine calcium antagonist, improves the ambulatory BP & HR profile by significant suppression of LVH in hypertensive CKD patients. 
  • Reduce urinary proteinuria than amlodipine, in protein-uric and hypertensive patients treated with renin-angiotensin blockades. 
  • Significantly decreases urinary albumin excretion without affecting serum creatinine concentration in hypertensive patients as compared to ACE inhibitor benazepril. 


  • Class of medications: Angiotensin II receptor antagonists
  • Newer angiotensin receptor blocker, very useful for the management of patients with mild-to-moderate hypertension.
  • An important alternative as the first-line treatment of hypertension. 
  • Produces greater reductions in both systolic blood pressure (SBP) & diastolic blood pressure (DBP) when compared with losartan. 
  • Exert its PPARgamma enhancing activity clinically in obese or overweight type 2 diabetic patients as compared to candesartan.


  • The combination therapy was more effective in reducing BP than either drug in monotherapy without affecting glucose homeostasis. 
  • Combination therapy with Cilnidipine & Telmisartan is more effective than treatment with Cilnidipine & Telmisartan alone & exhibits additive protective effects on renal & cardiac organs. 
  • Cilnidipine & telmisartan, synergistically decreased plasma aldosterone concentrations and pulse wave velocity for preventing vascular complications. 


Cilnidipine 10 mg + Telmisartan IP 40 mg


  1. Heart Attack
  2. Diabetics induced hypertension
  3. Vascular complications
  4. Hypertension